Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 Mutations

Familial Cancer

Volumn 9, Issue 3, 2010, Pages 283-287

  Steffensen, Ane Y ^a   Jønson, Lars ^a   Ejlertsen, Bent ^a   Gerdes, Anne Marie ^a   Nielsen, Finn C ^a   Hansen, Thomas V O ^a  

^a Rigshospitalet   (Denmark)

Author keywords

BRCA1; BRCA2; Breast cancer; Double heterozygote; Mutation; Ovarian cancer

Indexed keywords

ALANINE; ARGININE; BRCA1 PROTEIN; BRCA2 PROTEIN; GLUTAMINE; GLYCINE; NUCLEOTIDE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BREAST CANCER; CANCER FAMILY; CANCER RISK; CANCER SCREENING; CASE REPORT; EXON; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; HETEROZYGOTE; HUMAN; MALE; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON;

BASE SEQUENCE; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; DENMARK; FAMILY; FEMALE; FRAMESHIFT MUTATION; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; MUTATION, MISSENSE; OVARIAN NEOPLASMS; PEDIGREE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78650180384     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-010-9345-6     Document Type: Article

References (35)

1. Nathanson KL, Wooster R, Weber BL (2001) Breast cancer genetics: what we know and what we need. Nat Med 7:552-556
2. http://www.research.nhgri.nih.gov/bic/
3. Thomassen M, Hansen TV, Borg A et al (2008) BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol 47:772-777
4. Hansen TV, Bisgaard ML, Jonson L et al (2008) Novel de novo BRCA2 mutation in a patient with a family history of breast cancer. BMC Med Genet 9:58
5. Hansen TV, Steffensen AY, Jonson L et al (2010) The silent mutation nucleotide 744 G - > A, Lys172Lys, in exon 6 of BRCA2 results in exon skipping. Breast Cancer Res Treat 119:547-550
6. Hansen TO, Jonson L, Albrechtsen A et al (2009) Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breastovarian cancer families. Breast Cancer Res Treat 115:315-323
7. Neuhausen S, Gilewski T, Norton L et al (1996) Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 13:126-128
8. Thorlacius S, Olafsdottir G, Tryggvadottir L et al (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13:117-119
9. Hansen TV, Ejlertsen B, Albrechtsen A et al (2009) A common Greenlandic Inuit BRCA1 RING domain founder mutation. Breast Cancer Res Treat 115:69-76
10. Baralle D, Baralle M (2005) Splicing in action: assessing disease causing sequence changes. J Med Genet 42:737-748
11. Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31:3812-3814
12. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894-3900
13. Ferrer-Costa C, Gelpi JL, Zamakola L et al (2005) PMUT: a webbased tool for the annotation of pathological mutations on proteins. Bioinformatics 21:3176-3178
14. Reese MG, Eeckman FH, Kulp D et al (1997) Improved splice site detection in Genie. J Comput Biol 4:311-323
15. Hebsgaard SM, Korning PG, Tolstrup N et al (1996) Splice site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res 24:3439-3452
16. Yeo G (2004) Burge CB: maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11:377-394
17. Leegte B, van der Hout AH, Deffenbaugh AM et al (2005) Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. J Med Genet 42: e20
18. Friedman E, Bar-Sade Bruchim R, Kruglikova A et al (1998) Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet 63:1224-1227
19. Bell DW, Erban J, Sgroi DC et al (2002) Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Cancer Res 62:2741-2743
20. Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20:1480-1490
21. Smith M, Fawcett S, Sigalas E et al (2008) Familial breast cancer: double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes. Fam Cancer 7:119-124
22. Choi DH, Lee MH, Bale AE et al (2004) Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 22:1638-1645
23. Caldes T, de la Hoya M, Tosar A et al (2002) A breast cancer family from Spain with germline mutations in both the BRCA1 and BRCA2 genes. J Med Genet 39: e44
24. Giannini G, Capalbo C, Ottini L et al (2008) Clinical classification of BRCA1 DNA missense variants: H1686Q is a novel pathogenic mutation occurring in the ontogenetically invariant THV motif of the N-terminal BRCT domain. J Clin Oncol 26:4212-4214
25. Glover JN (2006) Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain. Fam Cancer 5:89-93
26. Williams RS, Bernstein N, Lee MS et al (2005) Structural basis for phosphorylation-dependent signaling in the DNA-damage response. Biochem Cell Biol 83:721-727
27. Goldgar DE, Easton DF, Deffenbaugh AM et al (2004) Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75:535-544
28. Chenevix-Trench G, Healey S, Lakhani S et al (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66:2019-2027
29. Abkevich V, Zharkikh A, Deffenbaugh AM et al (2004) Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 41:492-507
30. Gomez Garcia EB, Oosterwijk JC, Timmermans M et al (2009) A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res 11: R8
31. Vallon-Christersson J, Cayanan C, Haraldsson K et al (2001) Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10:353-360
32. Clapperton JA, Manke IA, Lowery DM et al (2004) Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 11:512-518
33. Lovelock PK, Spurdle AB, Mok MT et al (2007) Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res 9: R82
34. Pyne MT, Brothman AR, Ward B et al (2000) The BRCA2 genetic variant IVS7 + 2T-> G is a mutation. J Hum Genet 45:351-357
35. Pensabene M, Spagnoletti I, Capuano I et al (2009) Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Ann Oncol 20:874-878